our platform
eci therapeutics develops
products that promote healing.
Our platform combines pathogen-reduced human platelet-rich plasma-derived growth factors with mucoadhesive excipients. That means we take human plasma, conduct steps to enhance its safety, and add molecules that enhance delivery and improve consistency. We do this to enhance the efficacy of the growth factors (for healing). ECI is evaluating the use of these products to promote the healing of ocular and dermal epithelial (surface cell) disorders such as Neurotrophic Keratopathy (NK), Ophthalmic Burns, Endothelial Diseases, Limb Stem Cell Deficiency, Ocular GvHD, Dry Eye Disease, Corneal Abrasions, Chronic Wounds, Skin Burns, and Ulcers.
ECI has robust patents protecting the formulation that combines serum-like plasma with novel excipients to create products ranging from liquid eye drops to healing gels, ointments, contact lenses, contoured bandages, and wound dressings.
Our novel products synergistically combine the immediate tissue-repairing benefits of platelet-rich plasma-derived growth factors with the sustained action of hyaluronic acid to provide fast-acting relief and long-lasting therapeutic action.
human platelet-rich plasma
Platelet-rich plasma contains high levels of growth factors and proteins. These components are known to promote cell proliferation, tissue regeneration, and repair, making them beneficial for mucosal health. Additionally, the plasma’s inherent composition resembles human tears, naturally hydrating dry mucosal membranes.
hyaluronic acid & chitosan
Hyaluronic acid has a range of properties that make it useful in a variety of applications. It is biocompatible, biodegradable, and non-toxic, making it a promising material for medical applications. Its mucoadhesive and therapeutic properties enhance the attributes of the products we develop.
Chitosan has a range of properties that make it useful in a variety of applications. It is biocompatibility, biodegradability, and non-toxicity making it a promising material for use in medical applications, while its mucoadhesive, bleeding control, antimicrobial and tissue-regenerative properties enhance the attributes of the products we develop.
our products
ECI’s novel products synergistically combine the immediate tissue-repairing benefits of platelet-rich plasma derived growth factors with the sustained action of hyaluronic acid, to provide both instant relief and long-lasting therapeutic action.
product safety
The safety of our products is paramount. To ensure that are products are as safe as possible pathogens, innovative and removal technologies like the INTERCEPT Blood System for Plasma and nanofiltration have been incorporated into our manufacturing process.
ECI has met with the FDA and aligned on an orthogonal (multi-step) safety plan meeting all regulatory requirements.